Jupiter Neurosciences announced progress for its lead product, Jotrol, which the company claims significantly improves resveratrol’s bioavailability and central nervous system (CNS) targeting. According to the company, this advancement addresses limitations of traditional resveratrol formulations that show poor absorption and limited clinical impact.
The company said Jotrol’s proprietary oral formulation achieves higher plasma concentrations and enhanced delivery to the brain, potentially supporting therapeutic benefits in neuroinflammatory and neurodegenerative diseases. Jupiter Neurosciences highlighted the importance of CNS penetration for treating conditions such as mild cognitive impairment, Alzheimer’s disease, and traumatic brain injury.
Jupiter Neurosciences also stated that Jotrol has completed a Phase I safety and pharmacokinetic trial, demonstrating increased systemic exposure compared to standard resveratrol. The company claims these results enable further clinical evaluation in CNS disorders where inflammation and oxidative stress play a key role.
The company reported ongoing plans to advance Jotrol into later-stage clinical trials targeting both rare and common neurological diseases. Jupiter Neurosciences said its broader pipeline focuses on CNS conditions linked to inflammation, aiming to leverage Jotrol’s formulation technology to improve therapeutic outcomes.
Financial details, timelines for upcoming trials, and potential partnerships were not disclosed. Jupiter Neurosciences emphasized that Jotrol represents its core strategy to overcome traditional resveratrol’s delivery challenges and expand treatment options in neurology.
